Eltanexor
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2016 (NCT02649790)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Exportin-1INHIBITOR
XPO1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
NC(=O)/C(=C/n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)c1cncnc1- Mol. weight
- 428.3 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297623 ↗
Also known as
- kpt-8602
- kpt-8602
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05010525 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2021 | Antengene Corporation |
| NCT04691141 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2021 | Antengene Corporation, Tianjin blood research institute |
| NCT02649790 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2016 | Karyopharm Therapeutics Inc |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Antengene Corporation | For profit | 2 | 2 | 1 | 2021 |
| Karyopharm Therapeutics Inc | For profit | 1 | 1 | 1 | 2016 |
| Tianjin blood research institute | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1